Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pazufloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 6/20 | 0.63 |
| ▸ | TOP2B known ✓ | Q02880 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TUBB | P07437 | 1/20 | 0.62 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.62 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.62 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.62 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.62 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.62 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.62 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazufloxacin SCHEMBL8386358 | 1.00 | KDM4E (1.00) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL34460 | 1.00 | KDM4E (1.00) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL29381001 | 1.00 | KDM4E (1.00) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL9873706 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL28659469 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL9872951 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL28064894 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL28087423 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL29380457 | 0.95 | KDM4E (0.91) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL4442183 | 0.95 | KDM4E (0.91) | KDM4EKMT2AAADATTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | disclosed |
| US-10865220-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2020014269-A9 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC, LLC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865220-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | TOP2A 199/4885TOP2B 248/4885KDM4E 3437/4885 |
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | TOP2A 199/4885TOP2B 248/4885KDM4E 3437/4885 |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | TOP2A 199/4885TOP2B 248/4885KDM4E 3437/4885 |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | TOP2A 199/4885TOP2B 248/4885KDM4E 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.